ID 32200
JaLCDOI
FullText URL
Author
Ohnoshi, Taisuke
Hiraki, Shunkichi
Ueda, Nobuo
Fujii, Masafumi
Machida, Ken-ichi
Ueoka, Hiroshi
Kawahara, Shin
Kozuka, Akira
Moritaka, Tomonori
Kodani, Tsuyoshi
Kamei, Haruhito
Kimura, Ikuro
Abstract

Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.

Keywords
non-small cell lung cancer
ifosfamide
cisplatin
vindesine
Amo Type
Article
Published Date
1991-10
Publication Title
Acta Medica Okayama
Volume
volume45
Issue
issue5
Publisher
Okayama University Medical School
Start Page
357
End Page
361
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT